2 recruiting, 2 withdrawn, 1 active not recruiting, 1 completed. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 2, Withdrawn 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Sarcomas: new trials by email Literature Review of Sarcomas trials Research Report on Sarcomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas BOLD-100, Doxorubicin 75 mg/m^2 - Sarcoma, Soft-tissue, Sarcoma | Phase 1 | Withdrawn | University Health Network, Toronto | 2026-03-30 | 2026-11-13 | |
| Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors ZL-6201 - Solid Tumors, Sarcomas | Phase 1 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 180 | 2026-03-02 | 2026-07-23 |
| Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas Cabozantinib - Ewing Sarcoma, Osteosarcoma | Phase 1 | Recruiting | Children's Hospital of Philadelphia | 30 | 2023-10-24 | 2026-09-03 |
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine - Sarcomas, Melanomas | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2021-12-14 | 2021-12-17 | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC ONC-392, Pembrolizumab, Docetaxel - Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 733 | 2020-09-16 | 2026-09-14 |
| Dendritic Cell Vaccination for Patients with Solid Tumors autologous dendritic cell vaccination - Glioblastoma, Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | University Hospital, Antwerp | 48 | 2010-05-03 | 2024-12-09 |
Sarcoma (6) · Carcinoma, Renal Cell (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Melanoma (2) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Mesothelioma, Malignant (1) · Neoplasms, Germ Cell and Embryonal (1) · Osteosarcoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Connective and Soft Tissue (6) · Adenocarcinoma (3) · Carcinoma (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Kidney Diseases (3) · Kidney Neoplasms (3) · Male Urogenital Diseases (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Skin Diseases (3)
Azacitidine (1) · Docetaxel (1) · Doxorubicin (1) · KP 1339 (1) · bintrafusp alfa protein, human (1) · cabozantinib (1) · pembrolizumab (1)
Children's Hospital of Philadelphia (1) · National Cancer Institute (NCI) (1) · OncoC4, Inc. (1) · University Health Network, Toronto (1) · University Hospital, Antwerp (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (4) · Australia (1) · Belgium (1) · Canada (1) · China (1)
David S Schrump, M.D. (1) · Theodore Laetsch, MD (1) · Tianhong Li, MD (1)
R44CA250824 (1)